CD38 and acute myeloid leukemia: To investigate the effects of the VEN/8-Cl-Ado combination treatment on LSC-enriched blasts from de novo and relapsed AML patients, we treated CD34+CD38− AML blasts from three patients with de novo AML and four patients with R/R AML with 10 nM VEN and 500 nM 8-Cl-Ado, for 24 h.